<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: The aim of this first large-scale long-term study was to investigate whether obstructive <z:hpo ids='HP_0010535'>sleep apnoea</z:hpo> (OSA) and/or <z:hpo ids='HP_0010536'>central sleep apnoea</z:hpo> (CSA) are associated with an increased risk of malignant <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> in patients with <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS AND RESULTS: Of 472 CHF patients who were screened for <z:e sem="disease" ids="C0037315" disease_type="Disease or Syndrome" abbrv="">sleep disordered breathing</z:e> (SDB) 6 months after implantation of a cardiac resynchronization device with cardioverter-defibrillator, 283 remained untreated [170 with mild or no <z:e sem="disease" ids="C0037315" disease_type="Disease or Syndrome" abbrv="">sleep disordered breathing</z:e> (mnSDB) and 113 patients declined ventilation therapy] and were included into this study </plain></SENT>
<SENT sid="2" pm="."><plain>During follow-up (48 months), data on appropriately monitored <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> as well as appropriate cardioverter-defibrillator therapies were obtained from 255 of these patients (90.1%) </plain></SENT>
<SENT sid="3" pm="."><plain>Time period to first monitored <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> and to first appropriate cardioverter-defibrillator therapy were significantly shorter in patients with either CSA or OSA </plain></SENT>
<SENT sid="4" pm="."><plain>Forward stepwise Cox models revealed an independent correlation for CSA and OSA regarding monitored <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> [<z:hpo ids='HP_0002104'>apnoea</z:hpo>-hypopnoea index (AHI) ≥5 h(-1): CSA HR 2.15, 95% CI 1.40-3.30, P &lt; 0.001; OSA HR 1.69, 95% CI 1.64-1.75, P = 0.001; AHI ≥15 h(-1): CSA HR 2.06, 95% CI 1.40-3.05, P &lt; 0.001; OSA HR 1.69, 95% CI 1.14-2.51, P = 0.02] and appropriate cardioverter-defibrillator therapies (AHI ≥5 h(-1): CSA HR 3.24, 95% CI 1.86-5.64, P &lt; 0.001; OSA HR 2.07, 95% CI 1.14-3.77, P = 0.02; AHI ≥15 h(-1): CSA HR 3.41, 95% CI 2.10-5.54, P &lt; 0.001; OSA HR 2.10, 95% CI 1.17-3.78, P = 0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: In patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>, CSA and OSA are independently associated with an increased risk for <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> and appropriate cardioverter-defibrillator therapies </plain></SENT>
</text></document>